Does ROSUVASTATIN Cause Hepatic cytolysis? 60 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 60 reports of Hepatic cytolysis have been filed in association with ROSUVASTATIN (Rosuvastatin Calcium). This represents 0.2% of all adverse event reports for ROSUVASTATIN.
60
Reports of Hepatic cytolysis with ROSUVASTATIN
0.2%
of all ROSUVASTATIN reports
0
Deaths
35
Hospitalizations
How Dangerous Is Hepatic cytolysis From ROSUVASTATIN?
Of the 60 reports, 35 (58.3%) required hospitalization, and 8 (13.3%) were considered life-threatening.
Is Hepatic cytolysis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ROSUVASTATIN. However, 60 reports have been filed with the FAERS database.
What Other Side Effects Does ROSUVASTATIN Cause?
Myalgia (3,958)
Dyspnoea (2,832)
Pain (2,758)
Drug ineffective (2,347)
Fatigue (2,208)
Rhabdomyolysis (2,173)
Arthralgia (1,879)
Asthma (1,843)
Muscle spasms (1,843)
Pain in extremity (1,686)
What Other Drugs Cause Hepatic cytolysis?
ACETAMINOPHEN (1,469)
ATORVASTATIN (681)
PEMBROLIZUMAB (601)
CARBOPLATIN (577)
METHOTREXATE (468)
SULFAMETHOXAZOLE\TRIMETHOPRIM (356)
PACLITAXEL (324)
ENOXAPARIN (307)
AMOXICILLIN (273)
VALACYCLOVIR (261)
Which ROSUVASTATIN Alternatives Have Lower Hepatic cytolysis Risk?
ROSUVASTATIN vs ROSUVASTATIN\ROSUVASTATIN
ROSUVASTATIN vs ROTIGOTINE
ROSUVASTATIN vs ROXADUSTAT
ROSUVASTATIN vs ROXICODONE
ROSUVASTATIN vs ROXITHROMYCIN